{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T04:21:06Z","timestamp":1780460466591,"version":"3.54.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006546","name":"Angelini Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior Reports"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ebr.2025.100782","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:38:53Z","timestamp":1748864333000},"page":"100782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A french real-world experience with cenobamate in patients with drug-resistant focal epilepsy: A retrospective observational study"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4096-8307","authenticated-orcid":false,"given":"Antoine","family":"Plaquevent","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floriane Le","family":"Goff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Chastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebr.2025.100782_b0005","unstructured":"Inserm. \u00c9pilepsie \u00b7 Inserm, La science pour la sant\u00e9 [Online]. 2017 [cited 2024 Aug 20]. Available from : https:\/\/www.inserm.fr\/dossier\/epilepsie\/."},{"key":"10.1016\/j.ebr.2025.100782_b0010","doi-asserted-by":"crossref","first-page":"712","DOI":"10.3389\/fneur.2017.00712","article-title":"The burden of Severely drug-Refractory epilepsy: a Comparative longitudinal evaluation of mortality, morbidity, resource use, and cost using german health insurance data","volume":"8","author":"Strzelczyk","year":"2017","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.ebr.2025.100782_b0015","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/brain\/awac042","article-title":"Cause-specific mortality and life years lost in people with epilepsy: a danish cohort study","volume":"146","author":"Dreier","year":"2023","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ebr.2025.100782_b0020","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/epi.13723","article-title":"The impact of seizures on epilepsy outcomes: a national, community-based survey","volume":"58","author":"Josephson","year":"2017","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.ebr.2025.100782_b0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1046\/j.1528-1157.2002.32201.x","article-title":"Seizure reduction and quality of life improvements in people with epilepsy","volume":"43","author":"Birbeck","year":"2002","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.ebr.2025.100782_b0030","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: a 30-Year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.ebr.2025.100782_b0035","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.ebr.2025.100782_b0040","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S1474-4422(20)30035-1","article-title":"30 years of second-generation antiseizure medications: impact and future perspectives","volume":"19","author":"Perucca","year":"2020","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.ebr.2025.100782_b0045","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/j.1528-1167.2011.03047.x","article-title":"Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis","volume":"52","author":"Costa","year":"2011","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.ebr.2025.100782_b0050","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/epi.12212","article-title":"Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies","volume":"54","author":"Steinhoff","year":"2013","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.ebr.2025.100782_b0055","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1212\/WNL.0000000000002864","article-title":"Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies","volume":"87","author":"Ben-Menachem","year":"2016","journal-title":"Neurology"},{"issue":"855","key":"10.1016\/j.ebr.2025.100782_b0060","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejphar.2019.05.007","article-title":"Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons","volume":"15","author":"Nakamura","year":"2019","journal-title":"Eur J Pharmacol"},{"issue":"879","key":"10.1016\/j.ebr.2025.100782_b0065","article-title":"Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate","volume":"15","author":"Sharma","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"22","key":"10.1016\/j.ebr.2025.100782_b0070","doi-asserted-by":"crossref","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","article-title":"Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures","volume":"94","author":"Chung","year":"2020","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.ebr.2025.100782_b0075","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(19)30399-0","article-title":"Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial","volume":"19","author":"Krauss","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ebr.2025.100782_b0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108429","article-title":"Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures","volume":"126","author":"Privitera","year":"2022","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2025.100782_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107796","article-title":"Cenobamate treatment of focal-onset seizures: quality of life and outcome during up to eight years of treatment","volume":"116","author":"Elizebath","year":"2021","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2025.100782_b0090","article-title":"Evaluation of Doc\u2019EDS: a french semantic search tool to query health documents from a clinical data warehouse","author":"Pressat-Laffouilh\u00e8re","year":"2022","journal-title":"BMC Med Inf Decis Making"},{"issue":"3","key":"10.1016\/j.ebr.2025.100782_b0095","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1002\/epi4.12757","article-title":"Real-world safety and effectiveness of cenobamate in patients with focal onset seizures: outcomes from an expanded access program","volume":"8","author":"Villanueva","year":"2023","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.ebr.2025.100782_b0100","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.seizure.2023.07.026","article-title":"Cenobamate in patients with highly refractory focal epilepsy: a retrospective real-world study","volume":"111","author":"Beltr\u00e1n-Corbellini","year":"2023","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.ebr.2025.100782_b0105","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/epi4.12959","article-title":"Treatment simplification to optimize cenobamate effectiveness and tolerability: a real-world retrospective study in Spain","volume":"9","author":"Rodr\u00edguez-Uranga","year":"2024","journal-title":"Epilepsia Open"},{"issue":"3","key":"10.1016\/j.ebr.2025.100782_b0110","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/epi.17874","article-title":"Add-on treatment with cenobamate is already effective at low doses in refractory focal epilepsy: a prospective observational study","volume":"65","author":"Novitskaya","year":"2024","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.ebr.2025.100782_b0115","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1007\/s00415-024-12510-1","article-title":"Cenobamate: real-world data from a retrospective multicenter study","volume":"271","author":"Lauxmann","year":"2024","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.ebr.2025.100782_b0120","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40263-024-01109-9","article-title":"Cenobamate as an Early adjunctive treatment in drug-resistant focal-onset seizures: an observational cohort study","volume":"38","author":"Winter","year":"2024","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ebr.2025.100782_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2024.107498","article-title":"Effectiveness and tolerability of cenobamate: a single center experience","volume":"209","author":"Saouda","year":"2025","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2025.100782_b0130","article-title":"Effectiveness and safety of adjunctive cenobamate for focal seizures in adults with developmental disability treated in clinical practice","volume":"18","author":"Connor","year":"2022","journal-title":"Epilepsy Behav Rep"},{"key":"10.1016\/j.ebr.2025.100782_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2023.107207","article-title":"Real-world analysis of retention on cenobamate in patients with epilepsy in the United States","volume":"197","author":"Stern","year":"2023","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2025.100782_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.950171","article-title":"Real-world Experience treating pediatric epilepsy patients with cenobamate","volume":"13","author":"Makridis","year":"2022","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.ebr.2025.100782_b0145","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/epi.16525","article-title":"Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study","volume":"61","author":"Sperling","year":"2020","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.ebr.2025.100782_b0150","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/ane.13659","article-title":"Onset of efficacy and adverse events during cenobamate titration period","volume":"146","author":"Steinhoff","year":"2022","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.ebr.2025.100782_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106952","article-title":"Efficacy of cenobamate for uncontrolled focal seizures in patients with previous epilepsy-related surgery: post hoc analysis of a phase 3, multicenter, open-label study","volume":"184","author":"Abou-Khalil","year":"2022","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2025.100782_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2024.107306","article-title":"Reductions in concomitant antiseizure medication drug load during adjunctive cenobamate therapy: post-hoc analysis of a subset of patients from a phase 3, multicenter, open-label study","volume":"200","author":"Aboumatar","year":"2024","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2025.100782_b0165","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.seizure.2022.02.003","article-title":"Efficacy and safety of adjunctive cenobamate: post-hoc analysis of study C017 in patients grouped by mechanism of action of concomitant antiseizure medications","volume":"96","author":"Brandt","year":"2022","journal-title":"Seizure"},{"key":"10.1016\/j.ebr.2025.100782_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109605","article-title":"Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies","volume":"151","author":"Krauss","year":"2024","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.ebr.2025.100782_b0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2022.106940","article-title":"Efficacy of cenobamate by focal seizure subtypes: post-hoc analysis of a phase 3, multicenter, open-label study","volume":"183","author":"Rosenfeld","year":"2022","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.ebr.2025.100782_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106592","article-title":"Efficacy of adjunctive cenobamate based on number of concomitant antiseizure medications, seizure frequency, and epilepsy duration at baseline: a post-hoc analysis of a randomized clinical study","volume":"172","author":"Rosenfeld","year":"2021","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.ebr.2025.100782_b0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/epi.17134","article-title":"Long-term individual retention with cenobamate in adults with focal seizures: pooled data from the clinical development program","volume":"63","author":"Sander","year":"2022","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.ebr.2025.100782_b0190","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1111\/epi.17091","article-title":"Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study","volume":"62","author":"Sperling","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.ebr.2025.100782_b0195","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.seizure.2024.04.017","article-title":"Efficacy and safety of adjunctive cenobamate based on patient etiology: post-hoc analysis of YKP3089C017 randomized clinical trial","volume":"118","author":"Xu","year":"2024","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.ebr.2025.100782_b0200","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40265-021-01661-4","article-title":"Third-generation antiseizure Medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis","volume":"82","author":"Lattanzi","year":"2022","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ebr.2025.100782_b0205","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1002\/epi4.12992","article-title":"The cenobamate KORK study-a prospective monocenter observational study investigating cenobamate as an adjunctive therapy in refractory epilepsy, with comparisons to historical cohorts treated with add-on lacosamide, perampanel, and brivaracetam","volume":"9","author":"Steinhoff","year":"2024","journal-title":"Epilepsia Open"},{"issue":"4","key":"10.1016\/j.ebr.2025.100782_b0210","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s40120-022-00400-5","article-title":"Dose adjustment of concomitant antiseizure Medications during cenobamate treatment: expert opinion consensus recommendations","volume":"11","author":"Smith","year":"2022","journal-title":"Neurol Ther"},{"issue":"3","key":"10.1016\/j.ebr.2025.100782_b0215","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/epi4.12936","article-title":"Spanish consensus on the management of concomitant antiseizure medications when using cenobamate in adults with drug-resistant focal seizures","volume":"9","author":"Carre\u00f1o","year":"2024","journal-title":"Epilepsia Open"}],"container-title":["Epilepsy & Behavior Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986425000425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589986425000425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T06:24:07Z","timestamp":1755671047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589986425000425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"alternative-id":["S2589986425000425"],"URL":"https:\/\/doi.org\/10.1016\/j.ebr.2025.100782","relation":{},"ISSN":["2589-9864"],"issn-type":[{"value":"2589-9864","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A french real-world experience with cenobamate in patients with drug-resistant focal epilepsy: A retrospective observational study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebr.2025.100782","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100782"}}